Clearmind Medicine finishes enrollment for Phase I/IIa Part C trial of CMND-100

Clearmind Medicine announced that it has completed patient enrollment for Part C of its Phase I/IIa study of CMND-100, a non‑hallucinogenic psychedelic‑derived candidate. The randomized, double‑blind, placebo‑controlled trial is being run at sites in the United States and Israel, including major academic medical centers. CEO Dr. Adi Zuloff‑Shani said the milestone shows continued momentum for the program.

The company indicated that finishing enrollment moves the program toward the upcoming data readout, which could affect investor expectations for future efficacy and safety results.

  • 1Clearmind Medicine completed patient enrollment for Part C of its Phase I/IIa trial of CMND-100.
  • 2Part C is a randomized, double‑blind, placebo‑controlled multiple‑dose study evaluating safety, tolerability and pharmacokinetics.
  • 3The trial is conducted at clinical sites in the United States and Israel, including Johns Hopkins University’s medical school, Yale’s School of Medicine, Tel Aviv’s Sourasky Medical Center and Hadassah Medical Center.
  • 4Dr. Adi Zuloff‑Shani, Chief Executive Officer, said the enrollment completion demonstrates continued momentum for the CMND‑100 program.

Sources